Cure8 research brief
This preclinical study suggests a plant extract (Pithecellobium clypearia) reduced inflammation and mucosal injury in a mouse model of ulcerative colitis and changed gut microbiota and purine metabolism—avenues that could inform future IBD research or drug discovery.
Researchers in microbiome and metabolomics, preclinical drug-discovery teams, clinicians following translational IBD research
This study (abstract) reports that Pithecellobium clypearia, a traditional Chinese medicinal extract, reduced disease activity and mucosal injury in a mouse model of DSS-induced ulcerative colitis.
The authors combined 16S rRNA microbiome profiling and metabolomics and found that treatment shifted gut bacterial composition (increasing Bacteroides, decreasing Escherichia–Shigella) and altered colonic purine metabolites (examples cited: xanthylic acid, aminoimidazole ribotide).
They link these microbial and metabolic changes to reduced pro-inflammatory cytokines and improved tight junction protein expression. The findings are preclinical and based on an animal model and molecular analyses reported in the article abstract.
The paper frames PC’s effects as preventive in the DSS model and proposes modulation of gut microbiota and purine metabolism as mechanisms. If you follow IBD research, this suggests a possible avenue for future therapeutic development or dietary/phytochemical interventions, but it does not provide evidence that PC is safe or effective in people.
Findings come from a DSS mouse model and combined 16S rRNA sequencing plus metabolomics; human safety and efficacy are not demonstrated.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This preclinical study connects an herbal medicine to changes in gut microbiota, inflammation, and intestinal barrier function in a mouse model of ulcerative colitis — findings that could inform future research on new...
This preclinical study suggests a plant-derived compound (euscaphic acid) can reduce inflammation and oxidative stress and alter the gut microbiota in a mouse model of ulcerative colitis, pointing to possible microbiome-...
This study identifies a compound that improved inflammation, barrier integrity, and microbiome/metabolite signatures in a mouse model of ulcerative colitis—areas that matter for symptom control and disease biology in...
